These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 2022970)
1. Determination of proliferative activities in human brain tumor specimens: a comparison of three methods. Morimura T; Kitz K; Stein H; Budka H J Neurooncol; 1991 Feb; 10(1):1-11. PubMed ID: 2022970 [TBL] [Abstract][Full Text] [Related]
2. In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67. Morimura T; Kitz K; Budka H Acta Neuropathol; 1989; 77(3):276-82. PubMed ID: 2922990 [TBL] [Abstract][Full Text] [Related]
3. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787 [TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical evaluation of proliferative activity in human brain tumours. Girino M; Riccardi A; Danova M; Gaetani P; Butti G; Giordano M; Cuomo A Anal Cell Pathol; 1990 Sep; 2(5):269-75. PubMed ID: 2275874 [TBL] [Abstract][Full Text] [Related]
5. Immunostaining for proliferating cell nuclear antigen: its role in determination of proliferation in routinely processed human brain tumor specimens. Khoshyomn S; Maier H; Morimura T; Kitz K; Budka H Acta Neuropathol; 1993; 86(6):582-9. PubMed ID: 7906072 [TBL] [Abstract][Full Text] [Related]
6. The relationship between Ki-67 labeling and mitotic index in gliomas and meningiomas: demonstration of the variability of the intermitotic cycle time. Schröder R; Bien K; Kott R; Meyers I; Vössing R Acta Neuropathol; 1991; 82(5):389-94. PubMed ID: 1767633 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of proliferative cells. Mokrý J; Nĕmecek S Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626 [TBL] [Abstract][Full Text] [Related]
8. Proliferative potential of brain tumors. Analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Shibuya M; Ito S; Miwa T; Davis RL; Wilson CB; Hoshino T Cancer; 1993 Jan; 71(1):199-206. PubMed ID: 8416716 [TBL] [Abstract][Full Text] [Related]
9. Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling. Lee KS; Yang WI Yonsei Med J; 1992 Sep; 33(3):265-71. PubMed ID: 1363339 [TBL] [Abstract][Full Text] [Related]
10. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Cher ML; Chew K; Rosenau W; Carroll PR Prostate; 1995 Feb; 26(2):87-93. PubMed ID: 7855002 [TBL] [Abstract][Full Text] [Related]
11. A correlative study of in vivo and in vitro labeling index using bromodeoxyuridine in human brain tumors. Kharbanda K; Dinda AK; Sarkar C; Karak AK; Dhir R; Mathur M; Roy S J Neurooncol; 1995; 23(3):185-90. PubMed ID: 7673980 [TBL] [Abstract][Full Text] [Related]
12. [Cell kinetic analysis of human brain tumors by bivariate flow cytometric measurement of cellular DNA content and amount of incorporated bromodeoxyuridine]. Okuda Y; Taomoto K; Saya H; Ijichi A; Kudo H; Kokunai T; Tamaki N; Matsumoto S No To Shinkei; 1989 Apr; 41(4):383-90. PubMed ID: 2765301 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma. Ghazvini S; Kroll S; Char DH; Frigillana H Invest Ophthalmol Vis Sci; 1995 Dec; 36(13):2762-7. PubMed ID: 7499099 [TBL] [Abstract][Full Text] [Related]
14. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections. Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920 [TBL] [Abstract][Full Text] [Related]
15. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling. Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67(MIB-5) immunohistochemistry and in situ hybridization for histone mRNA. Muskhelishvili L; Latendresse JR; Kodell RL; Henderson EB J Histochem Cytochem; 2003 Dec; 51(12):1681-8. PubMed ID: 14623936 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of cell growth fraction in formalin-fixed and paraffin-embedded murine tissue. Birner P; Ritzi M; Musahl C; Knippers R; Gerdes J; Voigtländer T; Budka H; Hainfellner JA Am J Pathol; 2001 Jun; 158(6):1991-6. PubMed ID: 11395376 [TBL] [Abstract][Full Text] [Related]
18. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. Thor AD; Liu S; Moore DH; Edgerton SM J Clin Oncol; 1999 Feb; 17(2):470-7. PubMed ID: 10080587 [TBL] [Abstract][Full Text] [Related]
19. [Immunohistochemical approach to reveal the growth potential of uterine cancers using anti-BrdU antibody and Ki-67]. Yoshinouchi M Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2513-21. PubMed ID: 2614188 [TBL] [Abstract][Full Text] [Related]
20. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Hayashi Y; Fukayama M; Koike M; Kaseda S; Ikeda T; Yokoyama T Acta Pathol Jpn; 1993 Jun; 43(6):313-9. PubMed ID: 8346708 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]